References
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–1554.
- Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123:3230–3238.
- Rezania K, Soliven B, Baron J, et al. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012;53:371–380.
- Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;376: 2570–2581.
- Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;3:365–368.
- Verschuuren JJ, Huijbers MG, Plomp JJ, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;9:918–923.
- Hughes CL, Yorio JT, Kovitz C, et al. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. J Med Case Reports. 2014;8:455.
- Roche JC, Capablo JL, Ara JR. Myasthenia gravis in association with extrathymic neoplasia. Neurologia. 2014;29:507–509.
- Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.
- Gradolatto A, Nazzal D, Truffault F, et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimm. 2014;52:53–63.
- Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122:2856–2863.
- Steidl C, Connors JM, D, Gascoyne D. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. JCO. 2011;29:1812–1826.
- Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk. 2015;15:404–408.
- Corazzelli G, Angrilli F, D'Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–215.
- Oki T, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma. 2008;49: 883–889.